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ABSTRACT 
Receptor activator of NF-KB ligand (RANKL) plays a key role in osteoclast-induced bone resorption across a range of degenerative 
bone diseases, and its specific inhibition has been recently approved as a treatment for women with postmenopausal osteoporosis at 
high or increased risk of fracture in the United States and globally.ln the present study, we generated transgenic mice (TghuRANKL) 
carrying the human RANKL (huRANKL) genomic region and achieved a physiologically relevant pattern of RANKL overexpression in 
order to establish novel genetic models for assessing skeletal and extra skeletal pathologies associated with excessive RANKL and for 
testing clinical therapeutic candidates that inhibit human RANKL. TghuRANKL mice of both sexes developed early-onset bone loss, 
and the levels of huRANKL expression were correlated with bone resorption and disease severity. Low copy Tg5516 mice expressing 
huRANKL at low levels displayed a mild osteoporotic phenotype as shown by trabecular bone loss and reduced biomechanical 
properties. Notably, overexpression of huRANKL, in the medium copy Tg5519 line, resulted in severe early-onset osteoporosis 
characterized by lack of trabecular bone, destruction of the growth plate, increased osteoclastogenesis, bone marrow adiposity, 
increased bone remodeling, and severe cortical bone porosity accompanied by decreased bone strength. An even more severe 
skeletal phenotype developed in the high copy Tg5520 founder with extensive soft tissue calcification. Model validation was further 
established by evidence that denosumab, an antibody that inhibits human but not murine RANKL, fully corrected the hyper-
resorptive and osteoporotic phenotypes of Tg5519 mice. Furthermore, overexpression of huRANKL rescued osteopetrotic 
phenotypes of RANKL-defective mice. These novel huRANKL transgenic models of osteoporosis represent an important advance for 
understanding the pathogenesis and treatment of high-turnover bone diseases and other disease states caused by excessive RANKL. 
© 2014 American Society for Bone and Mineral Research. 
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Introduction 
Bone remodeling is a constant physiological process of bone resorption and formation. Osteoclasts initiate the remodeling 
cascade by removing bone matrix and subsequently osteoblasts 
refill these resorption cavities with organic bone matrix, which 
gradually attains its biomechanical strength and stiffness via 
mineralization.(ll In the healthy young adult skeleton, osteoblastic 
and osteoclastic activities are typically balanced so that skeletal 
integrity is preserved. Osteoporosis is a metabolic disease that is 
associated with unequilibrated bone remodeling resulting from 
decreased bone formation and/or accelerated bone resorption. As 
a result, refilling of resorption cavities can be incomplete, leading to 
progressive bone loss, increased bone fragility, and fracture risk (2J 
The cause of the increased bone remodeling is multifactorial, 
but a recently discovered cytokine, receptor activator of NF-KB 
ligand (RANKL), constitutes the master regulator of bone 
resorption.(3J RANKL, a type II transmembrane protein from the 
tumor necrosis factor (TNF) superfamily, binds and activates its 
cognate receptor RANK as a trimer, and it also exists in a soluble 
form.(4l Binding of RANKL to RANK initiates a signaling cascade 
essential for the differentiation, activity, and survival of 
osteoclasts(5'6l and subsequently for osteoclast-induced bone 
resorptionYl The effects of RANKL are physiologically counter-
balanced by the soluble decoy receptor osteoprotegerin (OPG), 
which inhibits the binding of RANKL to RANK on osteoclast 
progenitors by sequestering RANKL(7l and thereby limiting 
osteoclastogenesis.(4 l RANKL is broadly expressed not only in 
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bone cells including osteoblasts, osteocytes, and hyperplastic 
chondrocytes but also in a wide variety of tissues and specific 
cells such as spleen, heart, lung, brain, thymus, T and B 
lymphocytes, or mammary epithelia cells.(8'9l This expression 
pattern is consistent with the pleiotropic effects of RANKL in 
diverse tissues including lymphoid tissue organization, mammary 
gland development during pregnancy, hormone-driven mam-
mary cancer, cancer metastasis, and thermoregulation.(1ol 
Genetic defects impairing the function of RANKL or RANK both 
in mice and humans result in severe autosomal recessive 
osteopetrosis (AR0)(11l owing to impaired osteoclast formation, 
demonstrating that RANKL and RANK are indispensable for 
osteoclastogenesis. On the other hand, when RANKL overwhelms 
the effects of OPG, as occurs in OPG-deficient mice(12l and in 
postmenopausal osteoporosis,'l 3l the imbalance in the bone 
remodeling process results in bone loss and early-onset 
osteoporosis. In addition, estrogen or androgen deficiency in 
humans and rodents leads to increased RANKL expression that is 
possibly associated with increased bone loss and risk of 
fractures}13' 14l providing a rationale for the development of 
RANKL-targeted therapies. Indeed, clinical trials with denosumab, 
a fully human lgG2 monoclonal antibody that specifically binds 
human RANKL (huRANKL) with high affinity, showed an increased 
bone mass and reduced incidence of fractures in postmenopausal 
women with osteoporosis(lsl and in prostate cancer patients 
receiving androgen-deprivation therapy.(16l This antibody was 
recently approved for the treatment of postmenopausal women 
with osteoporosis and patients developing cancer-related bone 
loss. However, preclinical studies assessing the efficacy and safety 
of novel huRANKL inhibitors have been restricted so far to limited 
animal models expressing either nonhuman primate RANKL(l?l or 
chimeric murine/human RANKL.(lBl Importantly, the ability of 
human RANKL to potently activate murine RANK suggested to us 
that the creation of human RANKL transgenic mice could provide 
a useful model for studying high-turnover bone disease and 
other RANKL-induced pathologies without the need for 
frequent injections of recombinant human RANKL.(lBl In addition, 
controlled expression of huRANKL in transgenic mice is necessary 
because constitutive overexpression of soluble RANKL from early 
development is lethal at the late fetal stage.(19l 
This initial report provides an extensive characterization of 
several transgenic mouse lines (TghuRANKL) that overexpress to 
varying degrees human RANKL in tissues that normally express 
this cytokine. TghuRANKL mice of both sexes developed early-
onset osteoporosis and the severity of the osteoporotic 
phenotype was directly related to the levels of RANKL expression. 
Skeletal phenotypes of these mice mimicked moderate to severe 
human osteoporosis including trabecular bone loss, cortical 
porosity, and increased bone fragility, which was successfully 
reversed upon denosumab treatment. These mice represent the 
first genetic rodent models of osteoporosis involving over-
expression of huRANKL, which can be used to facilitate the 
understanding of RANKL-induced pathologies such as osteopo-
rosis, while also permitting the preclinical evaluation of 
denosumab and potentially other novel huRANKL inhibitors. 
Materials and Methods 
Mouse husbandry 
Osteopetrotic Rankt'es/tles mice, which bear a loss-of-function 
Rank/ mutation, were previously described.(2ol These and other 
mice were maintained and bred under specific pathogen-free 
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conditions in the animal facility of BSRC "Alexander Fleming". All 
animal procedures were approved and carried out in strict 
accordance with the guidelines of the Institutional Animal Care 
and Use Committee and the Region of Attica Veterinarian Office. 
Generation and genotyping of RANKL transgenic mice 
For the generation of huRANKL transgenic mice, a Not I fragment 
of 200 kb containing the huRANKL gene was isolated from a 
human genomic BAC clone (RP11-86N24, lmaGenes GmbH, 
Berlin, Germany) with pulse field gel electrophoresis. The excised 
band was subsequently run in 4% low melting agarose gel and 
isolated with ~-agarase (New England Biolabs, Hitchin, UK) 
digestion. After dialysis in microinjection buffer, the transgene 
was microinjected into the pronuclei of fertilized (C57BU6J x 
CBA/J)F2 oocytes, as described elsewhere.(21l To identify 
transgenic founder mice by Southern blot, DNA was isolated 
from tail biopsies, digested with BamHI, and hybridized with the 
microinjected fragment. Founder transgenic mice were bred with 
C57BU6J mice to establish the various transgenic lines. TgRANKL 
progeny were genotyped by PCR (5'TCTTCAACTAATGGTGTACG; 
5'TCT ACAAGGTCAAGAGCATG). 
Transgenic copy number 
Copy number of the transgene was determined by quantitative 
real-time PCR (qPCR) using tail DNA from the TghuRANKL mice 
and wild-type (WT) littermates (n = 8-9). qPCR was performed 
using SsoFast EVA Green Supermix (Bio-Rad, Hercules, CA, USA) on 
a Rotor-Gene 6000 RT-PCR machine (Corbett Life Science, Sydney, 
Australia). A common pair of primers complementary to both 
human and mouse RANKL gene sequences was used to amplify 
both genes (5' ACCTGTACGCCAACA TTTGC; 5'CTTGGGA TTTTGA-
TGCTGGD. For each sample, the Ct value of RANKL was 
normalized against the mouse HuR gene (5'AGGACACAGCTT-
GGGCTACG; 5'CGTTCAGTGTGCTGATTGCD and the values of both 
RANKL and HuR genes were extrapolated from their respective 
standard curves. 
Quantitative expression analysis 
Total RNA was extracted from various tissues using a monophasic 
solution of guanidine isothiocyanate and phenol according to 
the manufacturer's instructions (TRI Reagent, MRC, Cincinnati, 
OH, USA). After removal of DNA remnants with DNase I treatment 
(Sigma-Aldrich, St. Louis, MO, USA), first-strand eDNA was 
synthesized using 2 f..Lg of total RNA and M-MLV (Sigma-Aldrich), 
whereas qPCR was performed at 55°C for 35 cycles. Specific 
primer pairs were used for the quantitative expression analysis 
of human RANKL (5'ACGCGTATTTACAGCCAGTG; 5'CCCGTAAT-
TGCTCCAATCTG), mouse RANKL (5'TGTACTTTCGAGCGCAGATG; 
5' AGGCTTGTTTCATCCTCCTG), and mouse OPG (5'CTTGCCTTG-
ATGGAGAGCCT; 5'TCGCTCGATTTGCAGGTCD. The same primer 
pair used for RANKL copy number detection was also used for 
detecting both mouse and human RANKL expression. The 
samples were normalized to ~2-microglobulin expression 
(5'TTCTGGTGCTTGTCTCACTGA; 5'CAGTATGTTCGGCTTCCCA TTC). 
Relative expression was calculated as the fold difference 
compared with control values using Bio-Rad ReiQuant. For each 
experiment, two technical and three biological replicas were used. 
Histopathological analysis 
Femurs and tibias were fixed in 4% paraformaldehyde (PFA) for 6 
hours, decalcified in 13% EDTA, and embedded in paraffin. 
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Sections of 5-1-lm thickness were stained with hematoxylin/eosin. 
Osteoclasts were stained for TRAP activity using a leukocyte acid 
phosphatase (TRAP) kit (Sigma-Aldrich). Nondecalcified bones 
were embedded in methyl methacrylate, and stained for Von 
Kossa to visualize mineralized bone. For assessment of bone 
formation, mice were injected with 100 1-1L calcein (5 mg/ml), 6 
and 2 days before euthanization, and undecalcified bones were 
embedded in methyl methacrylate according to standard 
double-labeling protocols.(22l Ectopic calcification in soft tissues 
was detected after staining with 2% Alizarin Red S (Applichem, 
Gatersleben, Germany). 
Serum bone markers 
Serum levels of mouse tartrate-resistant acid phosphatase form 
Sb (TRACP-Sb), an osteoclast activity marker, was measured by 
enzyme-linked immunosorbent assay (ELISA) according to 
manufacturer's instructions (lmmunodiagnostic Systems, Bol-
don, UK). The levels of soluble human RANKL were quantified 
using a human RANKL Single-Piex assay kit (Millipore/Linco, St. 
Charles, MO, USA) with detection limit of the assay at 4.88 pg/ml. 
Biochemical markers and blood analysis 
Serum clinical chemistry tests (performed by Microanalysi SA, 
Athens, Greece), including glucose, urea, total cholesterol, 
creatinine, alanine aminotransferase (AL D, aspartate amino-
transferase (AL D, alkaline phosphatase (ALP), phosphorus, 
calcium, and ionized calcium were measured using a multichan-
nel auto analyzer (Architect c8000, Abbott Diagnostics, Abbott 
Park, IL, USA). Blood samples, obtained by heart puncture, were 
collected in EDTA-coated tubes and blood analysis was 
performed (by Microanalysi SA) using full automatic blood cell 
counter Model PCE 210 N (ERMA INC., Tokyo, Japan). 
Micro-CT 
Bones (femur and tibia) were fixed in PBS plus 4% paraformal-
dehyde (PFA) overnight at 4°C and then washed and stored in 
70% ethanol. Three-dimensional microarchitecture of the distal 
femur from 4-week-old or 3-month-old WT and transgenic mice 
was evaluated using a high-resolution SkyScan 1076 microtomo-
graphic imaging system (SkyScan, Kontich, Belgium). Images 
were acquired at 48 KeV, 200 rnA with a 0.5-mm aluminum filter. 
Three-dimensional reconstructions (8.8 mm cubic resolution) 
were generated using NRecon software (SkyScan) as previously 
described.(23l For the trabecular bone regions, we assessed 
the bone volume fraction (BV/TV, %), trabecular number 
(Tb.N, mm- 1), trabecular separation (Tb.S, mm), and the 
connectivity density (Con. Dens., mm- 3). Femoral cortical 
geometry was assessed in micro-computed tomography (mi-
cro-CT UCT40, Scanco Medical AG, Basserdorf, Switzerland) using 
50 continuous CT slides (600 1-1m) located at the femoral midshaft 
as previously described.(24l For cortical bone, we measured the 
bone volume fraction (BV/TV), cortical tissue volume (Ct.TV, 
mm\ bone volume (Ct.BV, mm3), marrow volume (BMV, mm3), 
and the average cortical width (Ct.Th, mm). 
Biomechanical test 
The femur was placed in the material-testing machine on two 
supports separated by the distance of 9.9 mm and load was 
applied to the middle of the shaft, thus creating a three-point 
bending test. The mechanical resistance to failure was tested 
using a servo-controlled electromechanical system (lnstron 1114, 
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lnstron Corp., High Wycombe, UK) with actuator displaced at 
2 mm/min. Both displacement and load were recorded. Ultimate 
force (maximal load, measured in Newtons), stiffness (slope of 
the linear part of the curve, representing the elastic deformation, 
N/mm), and elastic and plastic energy (area under the curve, up 
to and beyond the yield point, respectively; N/mm) were 
calculated from the load-displacement curves. 
Denosumab treatment 
Denosumab at the dose of 10 mg/kg was administered sub-
cutaneously in the medium-copyTg5519 mice (n = 14,7 females 
and 7 males) twice per week from the 4th week of age for a period 
of 6 weeks. Saline was administered in control experimental 
groups consisting ofT gSS 19 and WT littermates (n = 14, 7 females 
and 7 males per group). Body weight was recorded weekly for 
each mouse. At 1 0 weeks of age, all mice were euthanized and the 
long bones were collected for blinded histopathological analysis. 
In addition, blood was collected to assess serum TRACP-Sb levels 
(murine ELISA, lmmunodiagnostic Systems). 
Statistical analysis 
All results are expressed as mean ±standard error (SE). Student's 
t test was performed to compare means between two groups, 
and one-way analysis of variance (ANOVA) was performed to 
compare means of multiple groups. Values of p < 0.05 were 
considered significant; *p < 0.05, **p :s; 0.01, ***p :s; 0.001 when 
not otherwise specified. 
Results 
Generation, identification, and expression analysis in 
TghuRANKL mice 
To achieve a correct spatial pattern of huRANKL expression in 
mice, a 200-kb genomic fragment containing the whole human 
RANKL gene isolated from a BAC clone was used for transgenesis 
(Supplemental Fig. S1A). No gene other than RANKL is encoded 
within the microinjected fragment. Four transgenic founders, 
Tg5516, Tg5519, Tg5520, and Tg5521, carrying the huRANKL 
gene (TghuRANKL) were generated with pronuclear injections as 
shown by Southern blot analysis after genomic digest with 
BamHI and hybridization with the microinjected fragment 
(Fig. 1A). The Tg5521 line was not further studied because the 
founder was mosaic for the transgene and produced a limited 
number of transgenic mice. The transgene copy number was 
calculated in the remaining three transgenic lines using a 
common primer pair amplifying both mouse and human 
genomic sequences in qPCR (Fig. 18). The low copy Tg5516 
line (1 extra copy), the medium copy Tg5519 line (1 0 extra 
copies), and the high copy Tg5520 line (27 extra copies) were 
further characterized. From these lines, Tg5516 and Tg5519 
transmitted the transgene to offspring, whereas the Tg5520 male 
founder did not produce any progeny. Therefore, more extensive 
expression and phenotypic analysis was performed in transgenic 
lines Tg5516 and Tg5519. 
Comparative analysis of the levels of huRANKL expression in 
various tissues including bone, brain, spleen, thymus, kidney, 
lung, heart, and liver revealed that the medium copy Tg55191ine 
expressed huRANKL at significantly higher levels relative to the 
low copy Tg5516 line (Fig. 10. More specifically, Tg5519 mice 
overexpressed huRANKL in all tissues studied, with higher levels 
in bone, brain, spleen, and kidney. Notably, in both TghuRANKL 
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Fig. 1. Generation of huRANKL transgenic mice and comparative expression analysis. (A) Southern blot analysis on genomic DNA isolated from 
TghuRANKL founder and wr control mice. BAC digest was used as a positive control, whereas known molecular weights are indicated in kilobases (kb). 
(8) Copy number (en) of the integrated transgenes and the endogenous mouse RANKL in wr, TgSS 16, and TgSS 19 mice (n = 8- 9 per group) as well as in 
the Tg5520 founder. Comparative analysis of the expression levels of huRANKL (C) as well as of both human and mouse RANKL (0) in various tissues from 
Tg5516, Tg5519, and wr mice by qPCR (n = 3 per group). The expression levels of RANKL in transgenic tissues were statistically compared with 
endogenous RANKL levels in wr mice (0). Relative fold change of RANKL mRNA expression was normalized against 132-microglobulin mRNA. Mean ± SE; 
*p < O.OS, **p ~ O.Dl, ***p ~ 0.001 . 
lines the levels of huRANKL were dramatically increased in bone 
tissue, isolated from femurs and tibias after removal of bone 
marrow cells, in accordance with recent studies showing that 
osteocytes, former osteoblasts trapped in the bone matrix, are 
the major source of RANKL production.(2s> Importantly from a 
pathophysiology perspective, the pattern of huRANKL expres-
sion in various tissues from both transgenic lines closely followed 
the pattern of endogenous RANKL expression seen in WT mice 
(Supplemental Fig. 51 8). To enable comparison of the levels of 
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the huRANKL transgene in various tissues of TghuRANKL mice 
with those of the endogenous mouse RANKL in WT mice, a 
common primer pair recognizing both mouse and human RANKL 
eDNA was used in qPCR. Such relative expression analysis 
showed that the low copy Tg5516 line expressed RANKL at 
significantly higher levels compared with WT mice but much 
lower in comparison to the medium copy Tg5519 line (Fig. 1 0), 
confirming our previous results based on huRANKL expression 
(Fig. 1 Q. 
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To investigate whether the increased levels of huRANKL 
expression in transgenic mice influenced expression at the levels 
of endogenous mouse RANKL, we performed a similar analysis in 
tissues overexpressing huRANKL such as bone and spleen 
(Supplemental Fig. 51 C) using a primer pair that specifically 
amplifies mouse RANKL eDNA. Our results showed that the levels 
of mouse RANKL expression in such tissues were comparable 
between TghuRANKL and WT control mice, indicating that the 
overexpression of huRANKL and the subsequent pathology had 
no effect in enhancing or suppressing endogenous mouse 
RANKL mRNA expression. Moreover, increased levels of endoge-
nous OPG expression were detected in bone tissues from T g5519 
mice compared with Tg5516 and WT control mice, probably as a 
result of a negative feedback mechanism in response to 
huRANKL overexpression (Supplemental Fig. 51 0). The high 
copy Tg5520 founder also overexpressed huRANKL at all tissues 
studied (data not shown). At the protein level, the serum levels of 
soluble huRANKL protein were dramatically increased in the 
Tg55191ine (1 065 pg/ml ± 151, n = 11) and the Tg5520 founder 
(1 003 pg/ml) compared with Tg5516 mice (6.27 pg/ml ± 0.84, 
n = 7) and WT control mice (undetectable, n = 11 ). 
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Tg5516 mice (Supplemental Tables 51 and 52). Histopathological 
and quantitative micro-CT analysis of the metaphyseal region of 
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pronounced at 2 (Supplemental Fig. 52A) and 3 months of age 
(Supplemental Fig. S2A, Fig. 2A) in both males and females. 
Trabecular bone volume fraction (BVITV) was reduced nearly 
2.5-fold, and trabecular number (Tb.N) was reduced more than 
SO% in 3-month-old Tg5516 mice compared with WT controls 
(Fig. 2A). Furthermore, Tg5516 mice had significantly wider 
trabecular separation (245%) than WT mice, whereas the 
connectivity density was decreased by sixfold. In contrast, the 
mid-diaphysis cortical bone volume (Ct.BV) and thickness (Ct.Th) 
were similar in Tg5516 mice and WT controls as assessed by 
micro-CT analysis (Fig. 28, C). Notably, mid-diaphysis femurs 
from 3-month-old Tg5516 mice had reduced biomechanical 
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Fig. 2. Low-expressing Tg5516 mice developed trabecular bone loss and increased bone fragility. (A) Quantitative analysis of the trabecular bone in the 
metaphyseal region of the distal femurs in 3-month-old (n = 5-6 per sex) Tg5516 and WTfemale and male littermates with micro-CT. BV!TV (bone volume/ 
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properties such as ultimate force (-22%), stiffness (-34%), and 
plastic energy (-23%) as assessed by three-point bending tests 
(Fig. 20). Biochemical markers of bone turnover such as TRACP-
Sb were normal as well as serum alkaline phosphatase levels 
(Supplemental Table 52). These results demonstrate that the low 
huRANKL-expressing Tg5516 mice develop a mild osteoporotic 
phenotype characterized by trabecular bone loss and decreased 
bone strength in both males and females by the third month 
of age. 
Tg5519 mice overexpressing huRANKL develop severe 
osteoporosis 
Overexpression of huRANKL in Tg5519 mice led to severe bone 
loss that was already established from the first month of age in 
both males and females. Histologically, the metaphyseal regions 
of the distal femur and the proximal tibia were profoundly 
osteoporotic in the Tg5519 mice, exhibiting an almost complete 
absence of trabeculae by 3 months of age (Fig. 3A), which 
precluded quantitative bone measurements through micro-CT 
analysis. Cartilage abnormalities were also observed through 
the accumulation of cartilaginous remnants (shown as asterisks) 
mainly in the epiphysis of 4-week-old (Fig. 3A) and the 
metaphysis of 3-month-old Tg5519 mice (Fig. 3B), which 
gradually disappeared. No obvious disorganization of the growth 
plate of 1- or 2-month-old T g5519 mice was observed and the 
thickness of the various zones appeared similar to WT littermates. 
However, cellular density in the resting/proliferation zones 
appeared increased along with proliferation of the cartilaginous 
remnants in the epiphysis subjacent to the growth plate. 
Interestingly, Tg5519 mice displayed a progressive growth plate 
loss, already evident at 3 months of age, which almost 
disappeared by the age of 1 0 months (Fig. 3A). Growth 
retardation was not noticed in Tg5519 mice, even though the 
femoral length was modestly decreased in 3-month-old T g5519 
mice compared with WT controls (Supplemental Fig. 53). Staining 
of femurs with tartrate-resistant acid phosphatase (TRAP), an 
enzyme that is highly expressed in osteoclasts, revealed 
increased number of giant osteoclasts in 3-month-old Tg5519 
mice both at epiphysis (Fig. 3B) as well as the mid-diaphysis 
cortical region (Fig. 3(). 
The skeletal phenotype of the Tg5519 line was also 
pronounced in cortical bone. Histopathological analysis of 
cortical bone at the mid-diaphysis showed that Tg5519 mice 
had severe intracortical porosity when compared with WT 
littermates at 3 months of age (Fig. 3(). Von Kossa staining of 
undecalcified femur sections confirmed the presence of intra-
cortical pores (Fig. 30). Moreover, abundant fluorochrome 
incorporation, an index of intracortical (endosteal) bone 
formation, was identified in cortical bone of Tg5519 femoral 
diaphysis using the calcein double-labeling technique (Fig. 3E}, 
suggesting the presence of woven bone. In addition, abundant 
osteoclasts were present within the cortical bone area ofTg5519 
mice as opposed to WT cortical bones (Fig. 3(), indicating 
increased cortical bone remodeling. To confirm the presence of 
increased bone turnover in Tg5519 mice, we further evaluated 
the levels of serum biomarkers. The levels of serum alkaline 
phosphatase (ALP), a marker of bone formation activity, was 
2.5-fold increased in 4-week-old Tg5519 mice and nearly 1 0-fold 
in 3-month-old Tg5519 mice in comparison to WT control mice 
(Supplemental Fig. S4A), reflecting disease severity. As expected, 
the serum levels ofTRACP-Sb were also dramatically increased in 
3-month-old Tg5519 mice compared with WT control mice 
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(31.34 ± 1.2 versus 8.7 4 ± 0.6), indicating active bone resorption 
(Supplemental Fig. S4B). 
Cortical bone loss and cortical porosity increased progressively 
throughout life (Supplemental Fig. SSA). Micro-CT analysis of 
cortical bone at the mid-diaphysis confirmed the presence of 
intracortical porosity in 3-month-old Tg5519 mice (Fig. 4A). 
Tg5519 mice (n = 11) exhibited a significant decrease in cortical 
bone volume (Ct.BV, -26%), cortical bone volume fraction (BV /TV, 
- 38%), and cortical thickness (- 48%) compared with WT control 
mice (Fig. 4B). Interestingly, femurs of Tg5519 mice (Fig. 4A, B) 
display a significant increase in the bone marrow volume (BMV, 
+ 67%) and the cortical total volume (Ct.TV, + 26%) relative to WT 
littermates, indicating an increase in the bone width compared 
with WT mice. As expected, mid-diaphysis femurs from 3-month-
old Tg5519 mice (n = 1 0) displayed significant reduced bio-
mechanical properties such as ultimate force (-58%), stiffness 
(-70%), and plastic energy (-45%) relative to WT littermates as 
assessed by three-point bending tests (Fig. 4(). 
To investigate the disease status at an earlier time point, we 
assessed both the metaphyseal trabecular region of distal femurs 
and the cortical bone parameters in 4-week-old Tg5519 mice 
through micro-CT. Our results showed that by the 4th week of 
age there was already substantial trabecular bone loss 
(Supplemental Fig. SSB). Moreover, the extent of cortical porosity 
was quantified in two different cortical regions, near growth 
plate (Supplemental Fig. SSC) and at mid-diaphysis (Supplemen-
tal Fig. 550), showing more increased cortical porosity near 
growth plate. Because mid-diaphysis is already severely affected 
at the age of 3 months (Fig. 4B), it appears that during disease 
progression the cortical porosity was extended from metaphysis 
toward diaphysis. Moreover, the cortical bone was mainly 
characterized by open porosity (Supplemental Fig. SSC, D) 
implying a direct interaction with the bone marrow cells that 
probably contributed to the recruitment and maturation of 
osteoclast precursors. Collectively, these results indicate that 
huRANKL overexpression resulted in increased bone remodeling 
and "trabecularization" of the cortical bone. 
Apart from the severe bone phenotype, histological analysis 
also revealed progressively increased adipocyte numbers in 
bone marrow ofT g5519 mice apparent from the third month of 
age (Fig. 3A, Supplemental Fig. SSA). Increased marrow adiposity 
was inversely correlated with bone marrow cellularity in Tg5519 
mice from the 6th month of age (data not shown). Despite the 
severe bone phenotype, the Tg5519 mice appeared normal and 
no clinical chemistry abnormalities (Supplemental Table 52) 
other than elevated alkaline phosphatase levels were observed. 
Similarly to Tg5516 mice, no hematological abnormalities 
(Supplemental Table 51) were observed in Tg5519 mice. In 
addition, no gross histopathological lesions were detected in 
T g5519 mice with the exception of few scattered peribronchial 
inflammatory foci observed in the lungs of 3-month-old Tg5519 
mice (Supplemental Fig. 56). Soft tissue calcification was not 
observed in Tg5519 mice (data not shown). 
Severe osteoporosis and soft tissue calcification in the 
high copy Tg5520 founder 
The high copyTg5520 founder (Fig. 1 B) overexpressing huRANKL 
exhibited progressive kyphosis indicating severe osteoporosis 
and never gave progenies probably because of the severe 
skeletal phenotype. At 8 months of age, the Tg5520 founder was 
euthanized and the tissues were assessed histologically. 
Histological examination of the metaphyseal distal femurs 
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Fig. 3. Tg5519 mice overexpressing huRANKL developed trabecular bone loss, growth plate loss, marrow adiposity, increased osteoclastogenesis, 
intracortical porosity, and increased cortical bone remodeling. (A) Representative sections of metaphyseal distal femurs from 4-week-, 3-month-, 6-month-, 
and 1 0-month-old Tg5519 mice and WT littermates, stained with hematoxylin/eosin (HIE) (n = 6). Scale bar = 500 f..Lm. (B) Representative serial sections of 
distal femurs from 3-month-old Tg5519 and WT controls stained with H/E and TRAP (n = 6). Scale bar = 500 f..Lm. (C) Cortical bone porosity with increased 
osteoclastogenesis in 3-month-old Tg5519 mice. Representative serial sections of mid-diaphysis cortical bone stained with H/E and TRAP (n = 6). Scale 
bar = 100 f..Lm. (0) Von Kossa staining of cortical bone and (E} double calcein labeling in 3-month-old Tg5519 and WT mice. Asterisks indicate cartilage 
remnants in Tg5519 mice (A, 8). Scale bar = 100 f..Lm. 
revealed absence of trabecular bone, growth plate loss, and bone 
fractures (Fig. SA). Tg5520 founder also developed intracortical 
porosity, giant osteoclasts inside the cortical area (Fig. 58), and 
increased marrow adiposity (Fig. SA, B) similarly to Tg5519 mice. 
Interestingly, ectopic calcification was observed in soft tissues 
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like kidney (Fig. sq, heart (Fig. 50), lung (Fig. Sf), and tongue 
(Fig. SF) of the Tg5520 founder compared with WT control 
(Supplemental Fig. 57), as revealed by staining with hematoxylin/ 
eosin and Alizarin red, which specifically stains calcium 
phosphate deposits. 
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Fig. 4. Tg5519 mice developed cortical porosity and increased bone fragility. (A) Representative micro-CT 3D cortical reconstructions and (8) quantitative 
analysis of mid-diaphysis cortical bone in femurs from 3-month-old Tg5519 and WT mice with micro-CT (n = 6 for females and n = 5 for males). Ct.BV 
(cortical bone volume, mm3), BV!TV (bone volume/total volume), Ct.Th (cortical thickness, mm), Ct.TV (cortical total volume/mm3), BMV (bone marrow 
volume/mm\ (C) Altered biomechanical parameters of the femurs from 3-month-old Tg5519 and WT mice. Ultimate force (N); stiffness (N/mm); plastic 
energy (N-mm) (n = 6 for females and n = 4 for males). Mean ± SE; • p < 0.05, •• p ::; O.Ql , ••• p ::; 0.001. 
Transgenic rescue of RANKL-mediated osteopetrosis 
Subsequently, we investigated whether the huRANKL transgene 
was sufficient to rescue RANKL-mediated osteopetrosis. In the 
past, we identified a recessive loss-of-function Rank/ allele in 
Rankflesltles mice, causing severe osteopetrosis, failure of tooth 
eruption, defective lymph node organogenesis, and premature 
lethality similarly to Rank/-deficient mice.'20l Introduction of a low 
copy huRANKL transgene into the Rankltlesltles genome through 
crossings with the T g5516 line fully restored survival (not shown), 
body weight gain, and eruption of the lower incisors, although 
eruption of upper incisors was partial (Supplemental Fig. S8A, 8). 
Moreover, the osteopetrotic phenotype was rescued as 
shown by the presence of fully expanded bone marrow cavities 
in the long bones of Tg5516/Rankltlesltles mice (Supplemental 
Fig. 58(). However, the partial rescue of the tooth eruption 
(Supplemental Fig. 588) as well as failure of lymph node 
organogenesis (Supplemental Fig. 580) noticed in T g5516/ 
Rankfles/tles mice indicate that the low copy huRANKL transgene 
did not completely rescue the phenotype caused by a loss-of-
function mouse Rank/ allele. In contrast, a medium copy 
huRANKL transgene in Tg5519/Rankf1es/tles mice rescued the 
clinical signs (Supplemental Fig. S8A) and the osteopetrotic 
phenotype (Supplemental Fig. 58() of the Rank/ties/ties mice, 
including restoration of tooth eruption (Supplemental Fig. 588) 
and mesenteric lymph nodes organogenesis (Supplemental 
Fig. 580). Collectively, these results indicate that the levels and 
pattern of huRANKL expression in transgenic lines are adequate 
for the restoration of the osteopetrotic phenotype. Moreover, our 
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data show that the huRANKL transgene is fully active in mice, 
implying full activation of the mouse RANK receptor. 
Denosumab treatment inhibits bone resorption in 
Tg5519 mice 
We further investigated whether the severe osteoporotic 
phenotype developed in T g5519 mice could be suppressed 
and restored by denosumab, a human monoclonal antibody 
against human RANKL. Denosumab, at 1 0 mg/kg, was adminis-
tered subcutaneously in Tg5519 mice (n = 14) for a period of 
6 weeks starting from the 4th week of age where bone 
resorption was already established both at the trabecular and the 
cortical areas. Saline-treated WT and Tg5519 littermates were 
included to assess physiological bone structure and disease 
progression during the treatment period, respectively. Histologi-
cal analysis of distal femurs from saline-treated Tg5519 mice 
showed remarkable trabecular bone loss at 10 weeks of age, 
whereas treatment with denosumab resulted in preservation of 
trabecular bone in the metaphyses of Tg5519 mice (Fig. 6A). 
Moreover, the cortical porosity and the increased intracortical 
osteoclastogenesis developed in T g5519 littermates were 
completely suppressed upon denosumab treatment (Fig. 68). 
Denosumab treatment also fully reversed the increased serum 
levels of TRACP-Sb in Tg5519 mice back to the levels of WT 
littermates (Fig. 6(). Overall, these results demonstrate that the 
specific inhibition of human RANKL by denosumab treatment 
substantially reversed the severe osteoporotic phenotype of 
Tg5519 mice. 
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Fig. 5. High copy numberTg5520 founder developed trabecular and growth plate loss, cortical porosity, and soft tissue calcification. (A) Serial sections of 
metaphyseal distal femurs and (8) mid-diaphysis cortical bone from 8-month-old Tg5520 founder and WT control, stained with hematoxylin/eosin (H/E} 
and TRAP showed loss of trabecular bone and growth plate, fractures, cortical porosity, and giant osteoclasts. (0 Serial sections of kidney, (D) heart, 
(E) lung, and (F) tongue from the Tg5520 founder stained with hematoxylin/eosin (H/E} and alizarin red showed ectopic calcification. Scale bars: 
A, F = 500 J.Lm; 8 = SO J.Lm; C, D = 1 00 J.Lm. 
Discussion 
In the current study, we report the generation and characteriza-
tion of novel osteoporosis models by overexpression of huRANKL 
in transgenic mice carrying the human RANKL genomic locus. 
The gene structure of RANKL is highly conserved in mammals, 
consisting of 5 exons that span 33.9 kb in humans and 30.5 kb in 
mice, whereas RANKL homologues have been identified so far 
only in organisms that contain osteoclasts, ie, vertebrates. In 
mammals, the transcription of RANKL is controlled by multiple 
transcriptional enhancers, some of which reside in long distance, 
more than 70 kb, upstream from the transcription start site.(9l To 
achieve a physiologically relevant expression pattern of RANKL 
overexpression, a 200-kb genomic region, isolated from a BAC 
library, spanning the coding region as well as the regulatory sites 
of the huRANKL gene was used for microinjections into the 
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pronucleus of fertilized eggs. Large genomic transgenes derived 
from BAC clones are more likely to provide physiologically 
relevant expression patterns and copy dependent expression 
levels, regardless of position effects.(26l These effects were also 
verified in the TghuRANKL lines as the levels of huRANKL 
expression in various tissues were analogous to the transgene 
copy number and followed the expression pattern of endoge-
nous mouse RANKL gene. Mice from the low copy Tg5516 line 
expressed huRANKL in higher levels compared with WT 
littermates but much lower levels relative to the medium copy 
Tg5519 line. Previous studies have shown that RANKL is widely 
expressed in a variety of cell types both in skeletal and 
extraskeletal tissues.(Bl Our studies showed that mice from 
both TghuRANKL lines, Tg5516 and Tg5519, overexpressed 
huRANKL in all tissues shown to express endogenous RANKL in 
the WT controls. Notably, huRANKL was more highly expressed 
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Fig. 6. Therapeutic effects of denosumab in Tg5519 mice. Representative serial sections of metaphyseal distal femur (A) and mid-diaphysis cortical bone 
(B) stained with hematoxylin/eosin (HIE) and TRAP from Tg5519 mice treated either with saline or denosumab and WT littermates treated with saline 
(n = 14 mice per group). Scale bars: A = 500 ,_,..m; 8 = 100 ,_,..m. (C) Serum TRACP-Sb levels in Tg5519 mice treated with denosumab compared with those in 
saline-treated WT and Tg5519 littermates (n = 14 per group). Mean ± SE; ***p S 0.001. 
in the bone tissue, in accordance with recent genetic studies in 
mice revealing that osteocytes are the major source of RANKL 
production,(2sl stimulating osteoclast formation and remodeling. 
Further studies assessing the effect of huRANKL overexpression 
in extraskeletal tissues such as the brain and the immune system 
in Tg5519 mice could reveal novel pathological implications. 
TghuRANKL mice overexpressing human RANKL exhibited an 
early-onset osteoporotic phenotype in both sexes. Tg5516 mice 
expressing human RANKL at low levels displayed significant 
trabecular bone loss already established at the second month of 
age and reduced biomechanical properties compared with 
WT controls. In contrast, the cortical bone parameters as well as 
the serum bone remodeling markers measured were similar 
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between Tg5516 mice and WT mice, indicating the development 
of a mild osteoporotic phenotype. On the other hand, greater 
overexpression of human RANKL in the Tg5519 line resulted in 
severe osteoporosis characterized by lack of trabecular bones, 
destruction of the growth plate, and severe cortical bone 
porosity in the femur accompanied by decreased bone strength 
compared with WT littermates. Chondrocytes are presumably 
overexpressing RANKL, and either this source, or other sources, is 
promoting chondroclasis and growth plate loss that ultimately 
diminishes longitudinal bone growth. Osteoclast formation at 
the intracortical surfaces as well as serum markers of bone 
turnover such as TRACP-Sb were progressively increased in 
Tg5519 mice, indicating active bone resorption. Tg5519 mice 
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also displayed active bone formation and significantly increased 
serum alkaline phosphatase levels, which is consistent with 
increased remodeling activation that leads to osteoblast-
mediated refilling of a great number or volume of resorption 
spaces. Cortical porosity, the result of intracortical bone 
resorption, was particularly pronounced in the Tg5519 line. In 
humans, cortical porosity increases during aging and osteopo-
rosis progression<27l and is associated with decreased bone 
strength and may contribute to the increased fracture risk in such 
patients. Thus, the Tg5519 mice represent a unique animal 
model for the investigation of the pathogenetic mechanisms in 
cortical porosity as well as the evaluation of novel therapies 
through parallel analyses of both trabecular and cortical bone 
sites. 
In addition, Tg5519 mice developed a progressive increase in 
bone marrow adipocytes. In humans, accelerated marrow 
adiposity has been associated with aging and osteoporosis.'28l 
Previous studies have shown an inverse association between 
bone marrow adiposity and bone mineral density,<29l since 
osteoblasts and adipocytes are thought to differentiate from the 
same mesenchymal stem cells. Adipocyte infiltration into the 
bone marrow occurs during aging and estrogen deficiency as a 
result of increased adipogenesis within the bone marrow at the 
expense of osteoblastogenesis.'30'31 l However, the causal role of 
increased bone marrow fat in regulating bone density remains 
ambiguous. The progressive marrow adiposity observed in 
3-month-old Tg5519 mice accompanied the increased bone 
remodeling established already from the 4th week of age. Thus, 
our study indicates that the increase in marrow adiposity does 
not precede bone resorption but rather emerges after disease 
occurrence. The hematopoietic-to-adipogenic transition is 
certainly another interesting phenotype of the Tg5519 mice, 
which could be used to gain mechanistic insights into the role of 
RANKL in this phenomenon. 
Tg5519 mice displayed phenotypic similarities with the OPG-
deficient mice including early onset of trabecular bone loss, 
progressive growth plate destruction, cortical porosity, and 
increased bone remodeling.<12l In both cases, elevated serum 
alkaline phosphatase levels and greater quantity of fluorescent 
label in the cortical bone probably reflect the coupling of bone 
formation to bone resorption within the basic multicellular 
remodeling unit. However, compared with the high-expressing 
Tg5519 mice, OPG-deficient mice exhibited an even more severe 
skeletal phenotype. OPG-deficient mice also displayed medial 
calcification of the aorta and renal arteries'12l that was not 
apparent in Tg5519 mice. The effect of RANKL in vascular 
calcification remains somewhat ambiguous because of the 
opposing results derived from different studies,(32·33l but RANKL 
inhibitors including denosumab have been shown to inhibit 
vascular calcification in several animal models.'34l The high copy 
Tg5520 founder did exhibit extensive calcification in soft tissues 
like kidney, lung, heart, and tongue, which might be the first 
evidence that systemic RANKL overexpression can cause soft 
tissue calcification. 
Previous studies attempting to restore RANKL-mediated 
osteopetrosis through administration of soluble mouse 
RANKL'35l or transgenic expression of mouse RANKL in T and B 
lymphocytes resulted in partial rescuing.'36l Similarly, our results 
showed partial restoration of the RANKL-mediated osteopetrotic 
phenotype in the presence of a low copy huRANKL transgene but 
complete rescue of the skeletal and lymph node organogenesis 
phenotype upon huRANKL overexpression in Tg5519/Rankl1es/ tles 
mice. These results indicate that the levels and pattern of 
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huRANKL expression in transgenic lines are adequate for the 
restoration of the osteopetrotic phenotype, and could be further 
exploited for the development of novel therapeutic approaches 
that target cell-based local delivery of RANKL in ARO. 
Previous preclinical studies assessing the efficacy and safety of 
denosumab in animal models have been restricted so far to 
cynomolgus monkeys'17'37l as well as to knock-in mice express-
ing a chimeric murine/human RANKL.'18l A significant limitation 
of those chimeric knock-in mice is that their remodeling rate is 
lower and their bone mass higher than WT controls, which limits 
their utility for osteoporosis research. In contrast, the TghuRANKL 
mice exhibit early-onset osteoporosis secondary to greatly 
increased remodeling rate. Our results confirmed that inhibition 
of huRANKL by denosumab in Tg5519-treated mice not only 
prevented bone loss progression but also fully restored the 
"osteoporotic" trabecular and cortical bone structure. Further 
validating the TghuRANKL model, denosumab decreased serum 
TRACP-Sb to the level of WT controls, indicating normal activity 
of their endogenous RANKL. 
Collectively, our TghuRANKL mice constitute the first trans-
genic models of early-onset osteoporosis attributable to human 
RANKL overexpression and thus offer a unique system for 
understanding the pathogenesis of high-turnover bone diseases 
and for the preclinical evaluation of novel huRANKL inhibitors. In 
addition, further studies on TghuRANKL mice might reveal novel 
extraskeletal pathologies associated with RANKL overexpression. 
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